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Management of Cardiogenic Shock Complicating Acute Myocardial
Infarction: The Henry Ford Hospital Experience and Review of the
Literature

AH R. Moosvi, MD,* Mihai Gheorghiade, MD,' Sidney Goldstein, MD,^ and
Fareed Khaja, MD+
Cardiogenic shock complicating acute myocardial infarction (MI) carries a high mortality which in
some series prior to 1980 exceeded 80%. Neither the use of inotropic and vasopressor agents nor
intraaortic balloon counterpulsation was found to improve survival in this group of patients.
Intravenous thrombolytic agents improve survival in patients with acute Ml. but their role in
cardiogenic shock is unknown. Reports of the use trf surgical and mechanical interventions in patients
with severe left ventricular dysfunction were examined to determine if there was any benefit to be
derived from restoring blood flow to ischemic areas of the myocardium. It was found that urgent
placement of intraaortic halloon counterpulsation followed hy coronary bypass surgery may improve
survival rates and successful coronary angioplasty also appeared to benefit patients with cardiogenic
shock. Similar improvement in survival has been reported after successful coronary reperfusion. In
surgical series whh predominantiy nonmechanicat causes of shock, survival has varied from 40% to
88%. Data from our five-year experience in the management of Ml patients with cardiogenic shock
suggest that coronary revascularization with coronary angioplasty or bypass surgery improves
survival in patients with cardiogenic shock especially when performed within 24 hours (rfthe onset of
shock. (Heniy Ford Hosp MedJ 1991;39:240-4)

A

cute myocardial infarction (MI) is complicated by shock in
up to 15% of patients and carries a high mortality, exceeding 80% (1-6). After the introduction of coronary care units,
even though overall mortality decreased in M I , only 19% of patients with shock survived (7).

Definition
There is no consistent definition of cardiogenic shock in the
literature. Some earlier reports defined shock only on the basis
of hypotension (systolic blood pressures below 90 mm Hg),
while others insisted on the presence of peripheral circulatory
collapse (1-22). Cardiac index and wedge pressures have not
been included as part of the definition, even in more recent studies, because not all patients in these studies had Swan-Ganz
catheterization performed (23-25). In our study a patient was
considered to be in cardiogenic shock when: 1) arterial systolic
blood pressure was less than 80 mm Hg without drugs or intraaortic balloon pump support or less than 90 mm Hg with such
support; 2) there was no evidence of hypovolumia (pulmonary
capillary wedge pressure greater than 12 mm Hg) and cardiac index was low (< 2.2 L/min/m^); and 3) the patient demonstrated
clinical evidence of hypoperfusion (26).

Medical Therapy
Conventional medical therapy does not influence survival
in patients with cardiogenic shock (8-22). Although inotropic
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agents, such as isoproterenol, produce initial improvement of
hypotension in some patients with shock, they have not been
shown to improve survival. Failure is presumedly due to the
positive inotropic effect being achieved at the expense of increased myocardial metabolism (12-15). Norepinephrine is considered to be superior to isoproterenol in the treatment of patients with shock because it increases arterial blood pressure by
increasing systemic vascular resistance and, unlike isoproterenol, it improves myocardial lactate extraction and coronary perfusion (12,13). Binder et al ( I I) showed a smati improvement in
survival with norepinephrine. Similarly, digitalis does not produce any significant change in cardiac output, arterial pressure,
or systemic vascular resistance. This lack of hemodynamic benefit may be due to the fact that cardiogenic shock is initiated
by the loss of a large amount of myocardium (18). Vasoactive,
inotropic agents like dobutamine and dopamine have been utilized for the management of shock, but no benefit in survival has
been demonstrated (8,18-20).
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Intraaortic Balloon Counterpulsation
In a multicenter trial, Scheldt et al (27) studied the effects
of intraaortic balloon counterpulsation in 87 patients with cardiogenic shock and demonstrated hemodynamic improvement.
However, survival was nol improved. A recent preliminary report by Waksman et al (28) suggested that survival was better in
patients treated with balloon counterpulsation. However, in this
report coronary revascularization was performed in 67% of patients. Thus, it appears lhat balloon support combined with revascularization, rather than balloon support alone, improves
survival.

Thrombolytic Therapy
Intravenous thrombolytic agents have been shown conclusively to decrease mortality from MI excepl in patients with severe heart failure. In the latter, mortality was 70% in both streptokinase and placebo groups (29-32). In a study of 44 patients
with cardiogenic shock, Kennedy et al (33) reported survival of
58% of patients with successful reperfusion compared to 16%
when reperfusion with intracoronary streptokinase was unsuccessful.

Coronary Artery Bypass Surgery
In 1980, DeWood et al (34) demonstrated improved longterm survival in 19 patients treated with urgent coronary bypass
surgery. Although this was a small, uncontrolled study, the results suggested that 1) early revascularization salvaged jeopardized myocardium and improved survival, and 2) surgery was
feasible and indeed advantageous in a patient population considered to be "too sick for surgery." In other reports which included patients with predominanlly nonmechanical causes of
shock, revascularization resulted in rates of survival from 40%
to 88% (35-42).
There are several limitations in the surgical data on cardiogenic shock. First, surgical series are subject to considerable
selection bias and not all patients with shock undergoing angiography were considered eligible for surgical revascularization.
Second, il is difficult to compare various studies since the percentage of patients with surgically correctable mechanical
causes, such as ventricular septal rupture or papillary muscle
dysfunction, varies from one study to the other. Third, the definition of shock is not uniform in these studies. Fourth, like the
medical series, surgical studies are small and nonrandomized.

Percutaneous Transluminal
Coronary Angioplasty
Coronary angioplasty can be performed in acute MI with
reperfusion rates from 70% to 90% (43,44). Lee et al (45) studied the effect of coronary angioplasty on survival in 24 patients
with cardiogenic shock following acute MI. The 30-day survival
was 77% in patients with successful angioplasty versus 18%
in those whose angioplasty was unsuccessful. However, in this
study none of the patients admitted between 1975 and 1982
were candidates for coronary angioplasty and were therefore
treated conventionally. They served as historical controls for patients admitted between 1983 and 1985, all of whom were candi-
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dates for coronary angioplasty. Similarly, other studies have reported in-hospital survival of 59% to 71% when shock patients
were treated with either primary angioplasty or the combination
of successful thrombolysis and bypass surgery (23,24,46).

Henry Ford Hospital Study
The effects of revascularization by coronary angioplasty or
bypass surgery on survival were evaluated in 81 patients with
cardiogenic shock complicating acute MI admitted from January 1985 to May 1990 (26). Patients with MI in whom shock
was secondary to mechanical causes, such as ventricular septal
rupture or papillary muscle rupture, were excluded from the
study. There were 1,346 patients admitted with confirmed acute
MI during this period, of whom 81 (6%) patients with cardiogenic shock form the study population. Successful revascularization was achieved in 32 patients: by angioplasty in 22, bypass
surgery in 2, and angioplasty followed by bypass surgery in 8
patients. The nonrevascularized group consisted of 49 patients;
41 had conventional medical therapy and 8 had failed angioplasty.
The clinical characteristics and hemodynamic data obtained
at the onset of cardiogenic shock were similar in both groups.
Ejection fraction was low in all patients but was a little higher in
the revascularized patients (31 % versus 25%, P = 0.04).
The overati survival rate was 27% (22 of 81 patients). However, survival was significantiy better in revascularized patients
(18 [56%] of 32 patients]) compared to the nonrevascularized
group (4 [8%] of 49 patients]) (P < 0.0001). This survival difference persisted at a mean follow-up of 21 ± 15 months, being
50% in the revascularized group versus 2% in the nonrevascularized group (P < 0.0001). The mean time from development of
shock to revascularization in survivors was 12.4 ± 15 hours
compared to 58.5 ± 93 hours in nonsurvivors (P = 0.004). The
most important conclusion was that in-hospital survival was
77% (17 of 22 patients) when revascularization was performed
within 24 hours compared to 10% (I of 10 patients) when revascularization was performed after 24 hours (P = 0.0006).
Even though our institution's experience is a nonrandomized,
prospective observational study, we believe that the groups are
comparable. Except for revascularization, no other variable appeared lo contribute significantly to survival. These data suggest
lhat coronary revascularization improves survival in cardiogenic shock, especially when it is performed early.

Time From Shock to Revascularization
Just as time from onset of symptoms to administration of a
thrombolytic agent in acute Ml is critical for survival, a time
frame applies to the management of shock by performing revascularization procedures. DeWood et al (34) emphasized that
survival was 75% when intraaortic balloon counterpulsation
and surgery was performed within 16 hours from the onset of
symptoms compared to 29% if this was achieved later. In a report from the Mayo Clinic on 45 patients wilh cardiogenic
shock, the in-hospital survival was 71% with successful angioplasty compared to 29% when the procedure was unsuccessful. Ejection fraction is likely to improve when primary an-
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Fig I—Suggested management of chnical shock In acute myocardial infarction.

gioplasty is performed within 4 hours of symptoms in patients
with cardiogenic shock (23). Hence, early recognition of cardiogenic shock and prompt intervention are of prime importance.
An outiine for the diagnosis and management of patients who
develop hypotension during the course of acute MI is shown in
Figs 1 and 2.
Hands et al (3) reviewed the Multicenter Investigalion of the
Limitation of Infarct Size data base and found that enzymatic
evidence of infarct extension or reinfarction occurred in 23% of
patients in whom cardiogenic shock developed, compared to a
7% incidence among those in whom shock did not develop. The
mechanism by which revascularization improves survival remains to be defined, as shock usually occurs several hours to
days following actual total occlusion of the infarct artery. Autopsy studies have demonstrated necrosis of greater than 40% of
myocardium in patients who develop cardiogenic shock (47).
Such patients also show progressive necrosis with infarct extension (48-50). Left ventricular dilatation may occur early and
progress over time, leading to hemodynamic deterioration and
sometimes rupture (51-60). There is experimental evidence that
late reperfusion inhibits infarct expansion (60). It is possible that
revascularization in human cardiogenic shock may be beneficial
by preventing or limiting infarct extension and expansion and
left ventricular dilatation.
Predictors of shock include history of previous infarction, diabetes, age greater than 65 years, admission radionuclide ejection fraction less than 35%, and a peak creatine kinase MB determinalion greater than 160 lU/L (3). We propose that in the
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Fig 2—Suggested management of cardiogenic shock in acute
myocardial infarction.

clinical setting of acute MI, these predictors should be carefully
evaluated and patients with these factors be closely monitored
for hemodynamic deterioration. If deterioration develops, they
should be considered for emergency revascularization by percutaneous transluminal coronary angioplasty and/or coronary
artery bypass graft surgery.
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